Tenders Are Invited For Pharmaceutical Products - Medicines With The Active Ingredient Vareniclin (Atc: N07ba03)

Pharmaceutical Products - Medicines With The Active Ingredient Vareniclin (Atc: N07ba03). Completion Of Non-Exclusive Discount Agreements In Accordance With Section 130A (8) Sgb V For Finished Medicinal Products With The Active Ingredient Vareniclin (Atc: N07ba03) At Any Time As Part Of A So-Called Open House Model. A Contract Is Concluded With Every Pharmaceutical Company That Meets The Prerequisites For Participation. There Is No Exclusivity. The Accession Or Conclusion Of The Contract Can Take Place At Any Time And On The Same Conditions. Individual Contract Negotiations Are Not Carried Out. The Earliest Start Of The Contract Is 01.11.2025. Based On This, The Contract Term Is A Maximum Of 24 Months. The Contract Ends On October 31, 2027 Regardless Of The Beginning Of The Contract. Should The Aok Saxony-Anhalt Write Out Exclusive Contracts For The Active Substances During The Contract Term In Accordance With The Relevant Procurement Law Regulations, The Contracts Concluded In The Context Of This Publication Are Terminated In Accordance With The Contractual Regulations. The Present Publication Is Not The Allocation Of A Public Mandate Within The Meaning Of Section 103 Gwb Or The Public Procurement Law. In Order To Ensure A Most Extensive Level Of Transparency For The Intended Contract Conclusions, The Publication Is Published In The Supplement To The Official Journal Of The European Union. In The Absence Of A Corresponding Publication Form, The Order Announcement Is Used. The Resulting Conceptual Requirements, Such As The Procedural Name Open Procedure, Are Only Due To The Use Of This Announcement Form And The Publication Platform. Another Meaning, In Particular A Submission Under Public Procurement Law, Unless They Are Mandatory For Legal Reasons, Is Not Associated With This.